New schizophrenia drug passes early safety check in small study
NCT ID NCT01879722
First seen May 12, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This early-stage study tested an experimental drug called TAK-063 in 77 people—some with stable schizophrenia and some healthy Japanese volunteers. The main goal was to see if the drug is safe and tolerable when taken daily for a week. Researchers monitored side effects, lab tests, and vital signs. This study does not aim to cure schizophrenia, but to gather safety data for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Glendale, California, United States
Conditions
Explore the condition pages connected to this study.